Plant Name: Papaver somniferum
Taxonomic Information:
Plant ID: NPO9498
Plant Latin Name: Papaver somniferum
Taxonomy Genus: Papaver
Taxonomy Family: Papaveraceae
Plant External Links:
NCBI TaxonomyDB:
3469
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
Turkey; Italy; Indonesia; India; Vietnam; China; Thailand; South Korea; IraqTraditional Medicine System:
Indian Folk; Unani; Siddha; Ayurveda; TCM; HomeopathyMedicinal Functions:
Anodyne; Antispasmodic; Antitussive; Astringent; Diaphoretic; Emmenagogue; Expectorant; Homeopathy; Hypnotic; Narcotic; Sedative
Geographical Distribution:
Turkey; Italy; Indonesia; India; Vietnam; China; Thailand; South Korea; Iraq
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADORA3; HTR7; DRD1; DRD2; HTR2A; HTR1A; | |
| TSHR; OPRK1; OPRD1; OPRM1; | |
| PDE10A; | |
| PDE3A; | |
| BLM; GFER; HSD17B10; SENP6; | |
| CA2; | |
| MMP9; MMP1; MMP2; | |
| CASP3; | |
| NFKB1; | |
| LMNA; THPO; SIGMAR1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cysteine protease | CASP3 | Caspase-3 | P42574 | CHEMBL2334 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | SENP6 | Sentrin-specific protease 6 | Q9GZR1 | CHEMBL1741215 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | OPRK1 | Kappa opioid receptor | P41145 | CHEMBL237 |
| Peptide receptor (family A GPCR) | OPRD1 | Delta opioid receptor | P41143 | CHEMBL236 |
| Peptide receptor (family A GPCR) | OPRM1 | Mu opioid receptor | P35372 | CHEMBL233 |
| Phosphodiesterase 10 | PDE10A | Phosphodiesterase 10A | Q9Y233 | CHEMBL4409 |
| Phosphodiesterase 3 | PDE3A | Phosphodiesterase 3A | Q14432 | CHEMBL241 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | HTR7 | Serotonin 7 (5-HT7) receptor | P34969 | CHEMBL3155 |
| Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
| Small molecule receptor (family A GPCR) | DRD2 | Dopamine D2 receptor | P14416 | CHEMBL217 |
| Small molecule receptor (family A GPCR) | HTR2A | Serotonin 2a (5-HT2a) receptor | P28223 | CHEMBL224 |
| Small molecule receptor (family A GPCR) | HTR1A | Serotonin 1a (5-HT1a) receptor | P08908 | CHEMBL214 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | SIGMAR1 | Sigma opioid receptor | Q99720 | CHEMBL287 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0060089; molecular transducer activity | GO:0004985; opioid receptor activity | 2.111E-10 | 1.149E-06 | OPRD1, OPRK1, OPRM1, SIGMAR1 |
| BP | GO:0007610; behavior | GO:0048148; behavioral response to cocaine | 1.444E-08 | 2.859E-05 | DRD1, DRD2, HTR2A, OPRK1 |
| MF | GO:0005488; binding | GO:0051378; serotonin binding | 3.989E-07 | 2.429E-04 | HTR1A, HTR2A, HTR7 |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 1.309E-06 | 6.195E-04 | ADORA3, DRD1, DRD2, HTR1A, HTR2A, HTR7, OPRD1, OPRK1, OPRM1, SIGMAR1, TSHR |
| BP | GO:0009987; cellular process | GO:0031635; adenylate cyclase-inhibiting opioid receptor signaling pathway | 1.882E-06 | 8.536E-04 | OPRK1, OPRM1 |
| MF | Unclassified; | GO:0004872; receptor activity | 3.452E-06 | 1.367E-03 | ADORA3, DRD1, DRD2, HTR1A, HTR2A, HTR7, OPRD1, OPRK1, OPRM1, SIGMAR1, TSHR |
| MF | GO:0005488; binding | GO:0042923; neuropeptide binding | 3.685E-06 | 1.408E-03 | OPRD1, OPRK1, OPRM1 |
| BP | GO:0009987; cellular process | GO:0007210; serotonin receptor signaling pathway | 4.834E-06 | 1.671E-03 | HTR1A, HTR2A, HTR7 |
| MF | GO:0060089; molecular transducer activity | GO:0004993; G-protein coupled serotonin receptor activity | 4.834E-06 | 1.671E-03 | HTR1A, HTR2A, HTR7 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 7.396E-06 | 2.334E-03 | BLM, CASP3, DRD1, NFKB1, OPRM1, PDE3A |
| BP | GO:0007610; behavior | GO:0042755; eating behavior | 7.795E-06 | 2.391E-03 | OPRD1, OPRK1, OPRM1 |
| BP | GO:0009987; cellular process | GO:0014059; regulation of dopamine secretion | 7.795E-06 | 2.391E-03 | DRD2, HTR2A, OPRK1 |
| BP | Unclassified; | GO:0042310; vasoconstriction | 8.686E-06 | 2.591E-03 | HTR1A, HTR2A, HTR7 |
| BP | GO:0051179; localization | GO:0043266; regulation of potassium ion transport | 9.996E-06 | 2.759E-03 | DRD1, DRD2, HTR2A, OPRK1 |
| BP | GO:0032501; multicellular organismal process | GO:0001659; temperature homeostasis | 1.067E-05 | 2.832E-03 | DRD1, DRD2, HTR2A |
| BP | GO:0009987; cellular process | GO:0007198; adenylate cyclase-inhibiting serotonin receptor signaling pathway | 1.127E-05 | 2.909E-03 | HTR1A, HTR7 |
| BP | GO:0050896; response to stimulus | GO:0043278; response to morphine | 1.176E-05 | 2.909E-03 | DRD2, OPRK1, OPRM1 |
| BP | GO:0050896; response to stimulus | GO:0071312; cellular response to alkaloid | 1.292E-05 | 3.161E-03 | BLM, CASP3, OPRM1 |
| BP | GO:0032501; multicellular organismal process | GO:0051930; regulation of sensory perception of pain | 1.416E-05 | 3.388E-03 | OPRD1, OPRK1, OPRM1 |
| BP | GO:0065007; biological regulation | GO:0007190; activation of adenylate cyclase activity | 1.833E-05 | 3.941E-03 | ADORA3, DRD1, TSHR |
| BP | GO:0050896; response to stimulus | GO:0071242; cellular response to ammonium ion | 1.833E-05 | 3.941E-03 | CASP3, DRD1, OPRM1 |
| BP | Unclassified; | GO:0021853; cerebral cortex GABAergic interneuron migration | 1.877E-05 | 3.941E-03 | DRD1, DRD2 |
| CC | GO:0044464; cell part | GO:0043204; perikaryon | 1.882E-05 | 3.941E-03 | DRD2, OPRK1, OPRM1, PDE10A |
| BP | GO:0050896; response to stimulus | GO:0009314; response to radiation | 2.104E-05 | 4.243E-03 | BLM, CASP3, DRD1, DRD2, OPRK1, OPRM1 |
| BP | GO:0050896; response to stimulus | GO:0035094; response to nicotine | 2.506E-05 | 4.880E-03 | CASP3, DRD2, NFKB1 |
| BP | GO:0032501; multicellular organismal process | GO:0097746; regulation of blood vessel diameter | 2.532E-05 | 4.880E-03 | DRD1, HTR1A, HTR2A, HTR7 |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 2.644E-05 | 5.007E-03 | CASP3, DRD2, LMNA, MMP2, OPRD1 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.813E-05 | 5.147E-03 | CYP2C19, CYP2D6 |
| BP | GO:0065007; biological regulation | GO:0045761; regulation of adenylate cyclase activity | 3.323E-05 | 5.777E-03 | DRD2, OPRM1, TSHR |
| BP | GO:0065007; biological regulation | GO:0065009; regulation of molecular function | 4.686E-05 | 7.730E-03 | ADORA3, BLM, CASP3, CYP2D6, DRD1, DRD2, GFER, HTR2A, MMP9, NFKB1, OPRD1, OPRM1, THPO, TSHR |
| BP | GO:0051179; localization | GO:0051051; negative regulation of transport | 5.202E-05 | 8.211E-03 | DRD2, HTR2A, MMP9, NFKB1, OPRK1, OPRM1 |
| BP | GO:0023052; signaling | GO:0051584; regulation of dopamine uptake involved in synaptic transmission | 5.241E-05 | 8.211E-03 | DRD1, DRD2 |
| CC | GO:0044456; synapse part | GO:0043679; axon terminus | 6.087E-05 | 9.269E-03 | DRD2, OPRD1, OPRK1 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.514E-12 | 1.590E-10 | OPRD1, HTR7, ADORA3, HTR1A, OPRK1, OPRM1, HTR2A, DRD1, DRD2, TSHR |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 7.246E-09 | 3.804E-07 | HTR7, CYP2D6, CASP3, HTR1A, HTR2A, CYP2C19 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 2.238E-07 | 7.833E-06 | HTR1A, PDE3A, DRD1, DRD2, NFKB1, TSHR |
| 09160 Human Diseases | 09164 Substance dependence | hsa05032 | Morphine addiction | 6.496E-06 | 1.705E-04 | PDE10A, PDE3A, OPRM1, DRD1 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 2.260E-05 | 4.746E-04 | MMP1, MMP2, MMP9 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.692E-04 | 2.538E-03 | MMP1, MMP2, CASP3, MMP9, NFKB1 |
| 09160 Human Diseases | 09164 Substance dependence | hsa05030 | Cocaine addiction | 3.878E-05 | 6.787E-04 | DRD1, DRD2, NFKB1 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 3.348E-04 | 3.515E-03 | MMP2, CASP3, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 3.157E-04 | 3.515E-03 | MMP2, OPRM1, MMP9 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 2.230E-04 | 2.927E-03 | HTR2A, DRD1, DRD2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 4.301E-04 | 4.105E-03 | CASP3, MMP9, NFKB1 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 8.682E-04 | 6.784E-03 | CASP3, LMNA, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 5.546E-04 | 4.853E-03 | OPRD1, ADORA3, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 9.803E-04 | 6.862E-03 | CASP3, MMP9, NFKB1 |
| 09160 Human Diseases | 09163 Neurodegenerative diseases | hsa05012 | Parkinson's disease | 9.046E-04 | 6.784E-03 | CASP3, DRD1, DRD2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 1.443E-03 | 9.472E-03 | OPRD1, ADORA3, PDE3A |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | OPRM1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | OPRM1; OPRK1; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | OPRM1; DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR2A; HTR1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | DRD2; OPRK1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HTR2A; HTR1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | DRD2; OPRD1; OPRK1; HTR2A; |
| NA: NA | Benign prostatic hypertrophy | NA | DRD2; |
| I00-I99: Diseases of the circulatory system | Pulmonary hypertension | I27.0, I27.2 | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | OPRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Narcotic depression | F19.20, F32 | OPRM1; |
| J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Lateral sclerosis | G12.2 | HTR1A; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | OPRM1; DRD2; |
| NA: NA | Vomiting | NA | DRD2; |
| NA: NA | Episode | NA | HTR1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Erythropoietic porphyria | E80.0 | HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR1A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | General anesthesia | R20.0 | OPRM1; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| NA: NA | Malignant phaeochromocytoma | NA | DRD2; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | OPRM1; OPRD1; HTR1A; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA3; DRD2; HTR2A; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | OPRK1; |
| N00-N99: Diseases of the genitourinary system | Bladder disease | N30-N32 | OPRD1; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; ADORA3; |
| I00-I99: Diseases of the circulatory system | Maintain blood pressure in hypotensive states | I10 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | OPRM1; HTR7; DRD2; OPRD1; HTR1A; |
| NA: NA | Edema | NA | CA2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; OPRM1; HTR2A; HTR1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | DRD2; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MMP2; |
| K00-K95: Diseases of the digestive system | Pancreatitis | K85, K86.0K86.1 | HTR2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Headache | G43-G44, R51 | OPRM1; |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | OPRD1; |
| K00-K95: Diseases of the digestive system | Dermal necrosis | K05 | DRD2; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Idiopathic thrombocytopenic purpura | D69.3 | DRD2; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | MMP9; |
| NA: NA | Hepatitis C virus infection | NA | ADORA3; |
| I00-I99: Diseases of the circulatory system | Hemorrhoids | I84 | HTR2A; |
| K00-K95: Diseases of the digestive system | Constipation | K59.0 | OPRM1; |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | DRD2; |
| C00-D49: Neoplasms | Breast cancer | C50 | DRD2; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | HTR1A; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | OPRM1; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Depressive fatigue | R53.82 | DRD2; |
| NA: NA | Inflammatory diseases | NA | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | DRD2; PDE10A; |
| NA: NA | Hyperaemia | NA | DRD2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | HTR1A; |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| NA: NA | Peripheral sensory neuropathies | NA | HTR1A; |
| NA: NA | Peripheral vasoconstriction | NA | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperprolactinemia | E22.1 | DRD2; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | DRD1; DRD2; HTR1A; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | DRD2; |
| NA: NA | False perceptions | NA | DRD2; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Postpartum haemorrhage | O72 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | OPRD1; HTR1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Carcinoid syndrome | E34.0 | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Mild pain | R52, G89 | OPRM1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Hypoactive sexual desire disorder | F52.0 | HTR1A; |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Advanced stage Parkinson's disease | F02.3, G20 | DRD2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | DRD2; OPRD1; HTR2A; HTR1A; |
| NA: NA | Anxiety disorders | NA | HTR1A; |
| NA: NA | Acute nonspecific diarrhea | NA | OPRD1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Systemic pain | R52, G89 | OPRM1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; DRD2; OPRK1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cancer pain | R52, G89 | OPRM1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | NFKB1; ADORA3; MMP9; MMP2; CASP3; |
| J00-J99: Diseases of the respiratory system | Bronchitis | J20-J21, J42 | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Movement disorder | R25 | OPRM1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Analgesia | R52, G89 | OPRM1; |
| NA: NA | Bulimia nervosa | NA | HTR1A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | HTR1A; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MMP9; MMP2; |
| NA: NA | Social phobia | NA | HTR1A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | OPRM1; |
| I00-I99: Diseases of the circulatory system | Cardiotonic | I50 | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Moderate-to-severe acute pain | R52, G89 | OPRM1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Moderate-to-severe pain | R52, G89 | OPRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HTR7; HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep maintenance insomnia | F51.0, G47.0 | HTR2A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Acromegaly | E22.0 | DRD2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | OPRD1; |
| NA: NA | Corneal vascularity | NA | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | DRD2; OPRK1; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | DRD2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
| NA: NA | Schizoaffective disorder | NA | PDE10A; HTR1A; |
| NA: NA | Schizoaffective disorders | NA | DRD2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | OPRD1; MMP1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR7; DRD1; DRD2; HTR2A; PDE10A; HTR1A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | OPRM1; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; |
| K00-K95: Diseases of the digestive system | Gastrointestinal problems | K30-K31, Q40-Q41 | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | OPRM1; DRD1; DRD2; OPRD1; OPRK1; HTR1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | DRD1; DRD2; HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | DRD1; HTR1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | DRD2; HTR1A; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Opiate dependence | F11 | OPRM1; OPRK1; |
| H00-H59: Diseases of the eye and adnexa | Ophthalmic disease | H00-H59 | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | HTR2A; |
| NA: NA | Cervical dystonia | NA | HTR1A; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; DRD1; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | DRD2; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1; HTR2A; HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychosis | F20-F29 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; DRD2; HTR1A; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Eating disorder | E66, F50, I10-I16, I50 | HTR1A; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| K00-K95: Diseases of the digestive system | Opioid-induced constipation | K59.0 | OPRM1; |
| NA: NA | Chronic diarrhea associated with inflammatory bowel disease | NA | OPRD1; |
| NA: NA | Malignant essential hypertension | NA | DRD2; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | OPRM1; DRD2; |
| K00-K95: Diseases of the digestive system | Diarrhea-predominant IBS | K58.0 | OPRD1; OPRK1; |
| A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | OPRM1; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| NA: NA | Addiction | NA | HTR2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | OPRK1; |
| I00-I99: Diseases of the circulatory system | Ischemic heart diseases | I20-I25 | OPRD1; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3; |
| NA: NA | Itching | NA | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; CA2; DRD2; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
